TRENDING :  Market Movers  |  Top 50   SPY (-0.31%)    TSLA (-6.03%)    BYND (0.17%)    BTCUSD (%)    FTNT (-0.73%)    ELTK (-3.03%)    CANF (-7.48%)    ARQL (0.56%)    MCHP (-0.15%)    ONCS (-32.5%)    VXX (-0.95%)    IP (-1.4%)    INTC (-1.04%)    GTN (-1.44%)    GLW (0.1%)    ANY (-1.05%)    AMZN (0.12%)    AMPH (-1.4%)    ACAD (-1.57%)    ECOR (-13.74%)    DIS (-0.18%)    DFRG (1.48%)    CMG (-1.26%)    CGC (2.29%)    CCCL (-2.81%)

 BSTC - BioSpecifics Technologies Corp

$62.16 [-2.02][-3.14%]

Next Earnings

8/8/2019

BMO

Recommend
Trade Idea »



OPEN RECOMMENDATIONS

No recommendations found.


This list is limited to recommendations made in last 7 days only. Subscribe to a service to see all their recommendations.

TRADERS TRACKING $BSTC

No traders tracking are currently recommending this stock

TRENDING ARTICLES



ImmunoGen Plunges as FDA Recommends New Study for Lead Drug

05/16/19
Shares of ImmunoGen Inc IMGN have plunged approximately 32 The downside followed after the company announced FDA s recommendation of a new study on lead candidate mirvetuximab soravtansine Moreover ImmunoGen s shares have significantly underperformed the industry so far this year

Catalyst (CPRX) Q1 Loss Narrows, Firdapse Off to a Good Start

05/14/19
Catalyst Pharmaceuticals Inc 160 CPRX reported a loss of 1 cent per share in the first quarter of 2019 narrower than the Zacks Consensus Estimate of a loss of 13 cents and the year ago loss of 6 cents The company s revenues of 12 4 million in the first quarter of 2019 surpassed the

Zoetis (ZTS) Earnings Beat Estimates in Q1, Revenues Miss

05/02/19
Zoetis Inc 160 ZTS posted first quarter 2019 adjusted earnings of 88 cents per share excluding one time items which increased 17 year over year from 75 cents and beat the Zacks Consensus Estimate of 79 cents Total revenues rose 7 year over year to 1 46 billion but marginally missed

What's in Store for BioSpecifics (BSTC) This Earnings Season?

04/30/19
Shares of BioSpecifics Technologies Corp BSTC have increased 9 7 year to date compared with the 160 industry s growth of 10 9 In the las t report ed quarter the company s earnings beat the Zacks Consensus Estimate Moreover BioSpecifics earnings beat the Zacks